Intal 5mg / dose inhaler (Aventis Pharma) 112 dose

Type Pressurised aerosol inhaler (MDI)
Medicine Sodium cromoglicate 5mg/dose
Activation mechanism Non breath actuated
Dose counter No dose counter
Price £12.69 / 30 days
(based on 8 puffs / day)
Licences
  • Adult Asthma Licence
  • Adolescent Asthma Licence (age range not available)
  • Paediatric Asthma Licence (age range not available)

Spacers

There are 30 compatible spacers

Training material

Prescribing

Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.

As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.

Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.

Safety Advice Warnings

Advice on Administration

  • Consider use of a spacer device for suitable patients and formulations

Advice on drug withdrawal

  • Progressive withdrawal recommended

Discontinue due to test or exam

  • Discontinue if bronchospasm or decreased respiratory function occur

Dose changes (other conditions)

  • Use lowest dose at which effective control of asthma is maintained

Patient Counselling

  • Advise patient not to use for relief of acute attacks
  • Advise patients that maximal therapeutic benefit will take several weeks
  • Ensure patient has a fast acting bronchodilator available
  • Patient should seek medical advice if usual relief is diminished
  • Use regularly to maintain freedom from symptoms

Recommended monitoring

  • Check patient is using correct inhaler technique

Safety/advice in other condition

  • Not to be used to relieve an acute asthmatic attack
  • Systemic corticosteroids may be needed during periods of stress

Precautions

  • Breastfeeding
  • Bronchospasm
  • Pregnancy

Contraindications

  • None known

Side Effects

  • Aggravation of existing asthma
  • Anaphylaxis
  • Angioedema
  • Bronchospasm
  • Collapse
  • Cough
  • Dizziness
  • Dysuria
  • Headache
  • Hypersensitivity reactions
  • Hypotension
  • Joint pain
  • Joint swelling
  • Laryngeal oedema
  • Nasal congestion
  • Nausea
  • Pulmonary eosinophilia
  • Pulmonary infiltrates
  • Rash
  • Rhinitis
  • Throat discomfort
  • Unpleasant taste
  • Urinary frequency
  • Urticaria
  • Wheezing